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Abstract: The p-synephrine is the principal phytochemical found in bitter orange (Citrus aurantium).
This substance is widely included in dietary supplements for weight loss/body fat reduction due to its
potential benefits of increasing fat oxidation. For years, p-synephrine-containing dietary supplements
have been marketed without proper knowledge of their true effectiveness to enhance fat utilization,
especially when combined with exercise. However, the effects of p-synephrine on fat oxidation
during exercise have been investigated in the last few years. The aim of the current discussion is
to summarize the evidence on the effects of p-synephrine intake on fat oxidation and performance
during exercise. Previous investigations have demonstrated that the acute intake of p-synephrine does
not modify running sprint performance, jumping capacity, or aerobic capacity. However, the acute
intake of p-synephrine, in a dose of 2–3 mg/kg of body mass, has been effective to enhance the rate
of fat oxidation during incremental and continuous exercise. This effect has been observed in a range
of exercise workloads between 30% and 80% of peak oxygen uptake (VO2peak). The p-synephrine
has the ability to increase the maximal rate of fat oxidation during exercise of increasing intensity
without affecting the workload at which maximal fat oxidation is obtained (Fatmax). The effect of
p-synephrine on fat oxidation is normally accompanied by a concomitant reduction of carbohydrate
utilization during exercise, without modifying the energy expended during exercise. The shifting in
substrate oxidation is obtained without any effect on heart rate during exercise and the prevalence
of adverse effects is negligible. Thus, the acute use of p-synephrine, or p-synephrine-containing
products, might offer some benefits for those individuals seeking higher fat utilization during exercise
at low to moderate intensities. However, more research is still necessary to determine if the effect
of p-synephrine on fat oxidation during exercise is maintained with chronic ingestion, in order to
ascertain the utility of this substance in conjunction with exercise programs to produce an effective
body fat/weight loss reduction.
Keywords: alkaloids; body composition; carbohydrate sparing; weight loss; exercise
1. Introduction
The p-synephrine (4-[1-hydroxy-2-(methylamino)ethyl]phenol) is a phenylethylamine
derivative present in the fruits of several trees from Rutaceae family such as Bitter Orange
(Citrus aurantium), Seville Orange, Sour Orange, Green Orange, Zhi Shi, and Kijitsu. Ad-
ditionally, this phytochemical can be found in many other citrus species such as Nova
tangerines and Marr’s sweet oranges [1]. In its natural state, p-synephrine is the main
phytochemical in most of these fruits, and it is present in the range of 0.10–0.35% in
fruits of Citrus aurantium and in the range of 3.00–3.08% in dry extracts of this fruit [2].
However, the amount of p-synephrine can be artificially increased by concentrating the
extract of natural products, and p-synephrine may be in a concentration of up to 19% in
some commercially available dietary supplements [3]. This allows the intake of moderate
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amounts of p-synephrine in one capsule or scoop of dietary supplements without the
need of ingesting a large amount of fruit. Interestingly, p-synephrine became popular
as an active ingredient for thermogenics and weight-loss supplements due to the ban of
Ephedra species by the U.S. Food and Drug Administration in 2004 [4]. Several dietary
supplements companies substituted Ephedra with Citrus aurantium or p-synephrine because
they purportedly have the capacity to increase the metabolic rate at rest and enhance lipol-
ysis [2,5]. It is believed that, in the long term, the chronic ingestion of p-synephrine may
reduce fat mass through increased thermogenesis and fat oxidation, although there is no
clinical or research evidence to support this notion by using supplements containing only
p-synephrine. Despite the lack of evidence, p-synephrine is widely present in slimming,
weight loss, thermogenics, and supplements for meal replacement and its presence in the
market of weight-loss products is comparable to other stimulants with well-contrasted
efficacy such as caffeine [6]. In the last few years, some investigations have aimed to
determine the efficacy of p-synephrine to enhance fat utilization during exercise. This
knowledge may be essential for those individuals seeking body fat reduction as the partici-
pation in regular exercise is one of the best practices to produce effective body composition
changes. Understanding the additive action of p-synephrine intake and exercise may help
to integrate p-synephrine as weight-loss supplement in exercise programs for weight and
obesity management [7]. For these reasons, the aim of the current discussion is to sum-
marize the existing evidence on the effects of p-synephrine intake on substrate oxidation,
energy expenditure, and cardiovascular variables during exercise. With this discussion,
we aim to shed light on the utility of this substance to enhance fat mass loss when used in
combination with exercise.
2. Chemical Structure of p-Synephrine
Synephrine is an unspecific adrenergic agonist, which can exist in three different
positional isomers (ortho o-, para p-, and meta m-) [8]. The m-synephrine and o-synephrine
do not occur naturally in Citrus aurantium and they are not habitually present in plants’
extracts [9]. The m-isoform, also named phenylephrine, is considered the most potent
synephrine adrenergic agonist at α-1 adrenoceptors, when compared to the other positional
isomers [10]. The o-synephrine isoform has no pharmacological effect in humans and it has
not been found in dietary supplements [11]. The subtle structural and stereochemical dif-
ferences of p-synephrine and m-synephrine result in different adrenergic receptor binding
characteristics that lead to mechanistic differences. Specifically, the absence of adrenergic
receptor binding of p-synephrine provides the explanation for its lack of production of
harmful cardiovascular effects as compared to m-synephrine. Hence, while m-synephrine
can be considered as an alkaloid with a potent cardiovascular effect [12], p-synephrine or
Citrus aurantium intake are normally not associated to harmful cardiovascular events [13].
Additionally, each positional isomer can also be found in two enantiomeric forms
with different pharmacological and physiological activities. For example, p-synephrine
exists in nature in the l- or [R-(−)]-enantiomeric form, whereas synthetic p-synephrine like
synephrine hcl is a racemic mixture of the l- and d-enantiomeric forms. Based on receptor
binding, the synthetic form is believed to exert approximately half the pharmacological
activity of the naturally occurring p-synephrine [14]. This difference occurs because the
d- or [S-(+)]-form provides little or no binding to adrenergic receptors in contrast to the l-
form [14]. This is important because a recent report suggests that most dietary supplements
containing p-synephrine or Citrus aurantium do not contain the plant extract [15]. Therefore,
the efficacy of commercially available supplements may be reduced when compared to
natural products or plants’ extracts for the same amount of p-synephrine.
3. Binding Capacity and Mechanisms of Action
The purported effects of p-synephrine to enhance thermogenesis and fat oxidation at
rest and during exercise were based on its structural similarity with endogenous amine
neurotransmitters such as epinephrine and norepinephrine [11]. Due to this structure,
Nutrients 2021, 13, 233 3 of 9
p-synephrine has the ability to bind β-3 adrenoceptors [16]. As a result, p-synephrine
increases lipolysis at rest [17,18], although the evidence of enhanced lipolysis during
exercise is lacking [18]. The β-3 adrenoceptors are expressed in human white as well
as brown adipose tissue and in skeletal muscle, and they play a role in the regulation
of energy balance and glucose and fat homeostasis [19]. Therefore, p-synephrine may
increase resting metabolic rate and energy expenditure, although most of this evidence
in humans has been found when using dietary supplements containing p-synephrine
in addition to other co-ingredients [20]. Additionally, p-synephrine elicits an efficient
stimulation of beige adipocyte differentiation through β-3 stimulation with the support of
several beige adipocyte differentiation-inducing factors [21]. Hence, β-3 activation induced
by p-synephrine may be key to enhance fat utilization, especially in the skeletal muscle
where a large amount of fat can be used to provide energy for contraction. On the other
hand, p-synephrine has a low binding affinity for α- and β-1 and β-2 adrenoreceptors.
In comparison to norepinephrine, the binding of p-synephrine has been reported to be
about 40,000-fold less to β-1 and β-2 adrenergic receptors and approximately 1000-fold
less to α-1 and α-2 adrenergic receptors [16]. The lack of α-1, α-2, β-1, and β-2 adrenergic
receptor binding supports the lack of effects of p-synephrine on heart rate and blood
pressure [20], which translates into a low rating of cardiovascular and hemodynamic side
effects derived from acute and chronic p-synephrine ingestion.
Furthermore, p-synephrine can stimulate specific receptors in the brain. The p-
synephrine is a highly potent and selective agonist of Neuromedin U2 receptors (NMU2R).
Specifically, NMU2R is prominent in the hypothalamic regions and is known to be associ-
ated with regulation of several important physiological functions, including food intake,
energy balance, stress response, and nociception [22]. The activation of β-3 adrenergic
receptor and NMU2R may contribute to the lipolytic activity of p-synephrine and it is
believed that p-synephrine may aid in the regulation of food intake and energy home-
ostasis by active NMU2R on the central nervous system. In experiments carried out with
animals, in which the isolated rat liver was perfused in vivo after oral administration
of p-synephrine, it has been found that p-synephrine has a potent capacity to inhibit the
pyruvate dehydrogenase enzyme [23]. The decrease in the activity of the pyruvate dehydro-
genase enzyme indicates that p-synephrine can inhibit the transformation of carbohydrates
into lipids, which may also add to body fat homeostasis. Lastly, p-synephrine suppresses
the 3T3-L1 cell adipogenesis by reducing the expression level of CCAAT-enhancer-binding
protein α (C/EBPα) and peroxisome proliferator-activated receptor γ (PPARγ), which
subsequently leads to a reduction in the fatty acid-binding protein 4 (aP2) expression.
Specifically, different treatments with p-synephrine activate the protein kinase B (PKB/Akt)
pathway and sequentially inhibits glycogen synthase kinase 3β (GSK3β) activity [24].
The Akt signaling pathway plays a pivotal role in modulating adipogenesis while GSK3β
is a crucial protein involved in cell signaling [25]. The Akt phosphorylation (activation)
and the GSK3β phosphorylation (inactivation) induced by p-synephrine administration
reduced the expression of PPARγ, a nuclear receptor protein with an essential role in the
regulation of adipocyte differentiation. As a consequence of these effects, p-synephrine
inhibited adipogenesis and the differentiation of adipocyte in 3T3-L1 preadipocytes. Col-
lectively, this information suggests that p-synephrine may exhibit anti-adipogenic effects
via different signaling pathways, the suppression of adipogenesis-related proteins, and
improved regulation of energy balance and food intake.
4. Ergogenic Effect of p-Synephrine during Exercise
The structural similarity of p-synephrine with endogenous amine neurotransmitters
was the ground to hypothesize that this substance may increase exercise performance
through enhanced stimulation of the sympathetic nervous system [16]. However, as we
saw above, the characteristics of this alkaloid are different to other similar endogenous
amine due to low binding to adrenergic receptors. Despite this, p-synephrine was added to
the Monitoring Program of the World Anti-Doping Agency (WADA) in 2009 [26] because
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it has been considered as a substance with the potential of increasing exercise and sports
performance. The Monitoring Program was designed to assess the trends in the use
of substances that have the potential of being included in the WADA’s prohibited list.
However, substances in the Monitoring Program are not officially banned in sport because
the evidence to ascertain their efficacy to increase performance while affecting an athlete’s
health is not definitive. This means that p-synephrine has never been a banned substance,
but it is still included in the 2020 WADA Monitoring Program [26]. To date, the evidence is
pointing toward the lack of ergogenic activity of p-synephrine during exercise and sport,
although studies to demonstrate an increased exercise capacity after acute p-synephrine
intake are scarce and contradictory. For example, the acute intake of p-synephrine (3 mg/kg
of body mass) did not change running performance during 60-m and 100-m sprint races
and it did not affect single and repeated jumping capacity of sprinters when compared to
a placebo [27]. In addition, the ingestion of the same dose of p-synephrine did not increase
peak wattage nor the maximum oxygen uptake (VO2max) obtained during a ramp exercise
test in elite cyclists [28]. The only evidence demonstrating an increase in performance with
p-synephrine is a study reporting a higher capacity to perform squat repetitions during six
sets of exercise with a load equivalent to 80% of participants’ one-repetition maximum [29].
In this latter experiment, p-synephrine was ingested in a dose of ~1 mg/kg of body mass
for three days before the resistance exercise protocol. Further investigations are required
to clearly determine the ergogenic capacity of p-synephrine, which will help anti-doping
authorities decide if the substance should be included in the list of banned substances
or if it its should be stopped. To the authors’ opinion, the lack of ergogenic effect of this
substance during exercise, together with the low prevalence of adverse effects, discussed
below, does not support the inclusion of p-synephrine in the WADA Monitoring Program.
5. Effect of p-Synephrine to Shifting Substrate Oxidation during Exercise
Despite the wide popularity of p-synephrine in the weight-loss supplement market,
the efficacy of this substance to enhance fat oxidation during exercise has only been
demonstrated in the last few years (Figure 1). A first report in 2016 demonstrated that 3 mg
of p-synephrine/kg of body mass significantly enhanced fat oxidation during a cycling
test of increasing intensity in healthy individuals [5]. In this investigation, the acute
intake of p-synephrine increased the maximal rate of fat oxidation from 0.29 to 0.40 g/min
while it did not affect the exercise intensity at which maximal fat oxidation was achieved
(~56% VO2max). Similar findings have been obtained in elite cyclists with the same dose,
but, in this case, the p-synephrine induced a change in the rate of maximal fat oxidation
from 0.91 to 1.01 g/min, again without affecting Fatmax [28]. It is well established that
aerobically trained individuals have higher rates of fat oxidation during exercise than
untrained individuals [30] due to the different adaptations that aerobic training induces in
the cardiorespiratory system and within the skeletal muscle. The comparison of these two
studies [5,28] suggests that acute p-synephrine intake has the capacity of increasing the rate
of fat utilization during exercise irrespective of the fitness level of the individual. Hence,
it seems that the adaptations induced by aerobic training do not prevent the benefits of acute
p-synephrine intake on fat oxidation during exercise. Additionally, it has been found that
there is needed ingesting of at least 2 mg/kg of body mass of p-synephrine to significatively
increase the rate of fat oxidation during exercise of increasing intensity, while it sems that
the effect of this substance on fat oxidation plateaus at 3 mg/kg of body mass [31]. In
all these investigations [5,28,31], the acute intake of p-synephrine moves upwards the fat
oxidation–exercise intensity curve and the effect of p-synephrine was present at several
exercise intensities between 30% and 80% of VO2max. As a result, it seems safe to indicate
that p-synephrine is effective to enhance fat utilization during exercise of low to moderate
intensity. In fact, it has been recently found that 3 mg/kg of body mass of p-synephrine
increased the amount of fat oxidized during 1 h of exercise at Fatmax, equivalent to ~57%
VO2max from 33.6 to 37.3 ± 9.8 g [32]. Interestingly, the co-ingestion of p-synephrine and
caffeine does not produce a synergistic effect on fat oxidation during exercise over the
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benefit of these substances when they are ingested isolatedly [33]. In addition, it has been
found that the magnitude of the effect of p-synephrine on fat oxidation during exercise
of increasing intensity [33] and during steady-state exercise is similar to caffeine when
both substances are ingested in a dose of 3 mg/kg of body mass [32,34]. Collectively,
this evidence supports the benefit of acute p-synephrine intake to increase the rate of fat
oxidation during low- to moderate-intensity exercise. Although the magnitude of the effect
of this substance is small (increase of ~0.1 g of oxidized fat per min of exercise), the use
of p-synephrine-containing supplements may be an option for those individuals seeking
to maximize fat oxidation during endurance exercise. Additionally, p-synephrine may
also increase the rate of fat oxidation after exercise, although this effect requires further
research [18].
In all the abovementioned investigations, the increases in fat oxidation rate with
p-synephrine were accompanied by a concomitant reduction in carbohydrate oxidation
rates [28,30–32]. This is because p-synephrine does not modify energy expenditure rates at
any exercise intensity, which contradicts its potential thermogenic effect, at least during
exercise. Hence, it seems that p-synephrine produces a shifting in substrate oxidation
during exercise without affecting the energy expended with exercise [32]. The reduction of
carbohydrate oxidation is evident during exercise of increasing intensity [28] and during
steady-state exercise [32], and it may help individuals to spare muscle and liver glycogen
during exercise. Glycogen sparing through feeding or training with low carbohydrate avail-
ability has been found effective to increase some forms of aerobic exercise performance [35].
However, suggesting that p-synephrine may enhance aerobic exercise performance via
glycogen sparing is speculative. In any case, this potential ergogenic effect of p-synephrine
would be associated to exercise or sports performed of long duration and performed at
low to moderate intensity as this is the range of exercise intensities where p-synephrine
exerts the shifting in the substrates oxidized during exercise.
It is important to highlight that the capacity of p-synephrine to shifting substrate
oxidation during exercise is produced without affecting heart rate [28,30–32], although
a reduction in perceived exertion has been reported [36]. This is important from a prac-
tical view because it concedes to p-synephrine the capacity of increasing fat utilization
during exercise with minimal changes in the internal load of participants. Therefore, p-
synephrine can be used during exercise programs aimed to reduce fat mass without the
need of modifying exercise intensity or the use of heart rate as a determinant of exercise
intensity. Last, the mechanism underlying the capacity of p-synephrine to shifting fuel
utilization during exercise is not clear, although the increased lipid availability by greater
p-synephrine-induced lipolysis in adipose tissue [17,18] is believed to be the main mech-
anism driving a higher reliance on fat during exercise. However, further experiments
assessing p-synephrine-induced changes in blood and muscle tissue during exercise are
needed to unveil the exact mechanism(s) associated to the benefits of p-synephrine.
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During exercise the acute intake of p-synephrine has been i ef ective to enhance performance. Acute
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6. Adverse Side Effects with Acute and Chronic Ingestion of p-Synephrine
The acute intake of p-synephrine in healthy humans has not been associated with
side effects, and the safety of this substance is certified by studies with animals with doses
of up to 1000 mg/kg/day [37]. In a recent review that summarizes all published case
reports about adverse events in humans associated with dietary supplements containing
p-synephrine, the authors found that, in all cases, the presence of p-synephrine was not
linked to the cause of the adverse effect [20]. To this regard, by using a double-blind and
placebo-controlled study, healthy individuals given Citrus aurantium extract with 49 mg
p-synephrine twice a day for 60 days had no adverse effects with respect to heart rate,
blood pressure, blood chemistries, or blood cell counts [38]. Additionally, the intake of
49 mg of p-synephrine for 15 days produced no significant changes in heart rate, electro-
cardiograms, or systolic or diastolic blood pressures in healthy individuals [39]. These
well-controlled experiments suggest the safety of chronic p-synephrine/Citrus aurantium
intake, at least up to two months, when ingested in a dose of ~1 mg/kg. Other random-
ized experimental research hA evaluated the incidence of adverse effects in healthy and
active individuals following acute intake of ~1–3 mg/kg of p-synephrine and there was no
increase in ratings of headaches, gastrointestinal discomforts, muscle pain, or insomnia
when compared to a placebo [27,33] nor an impact on blood parameters [40]. Finally, the
addition of p-synephrine to caffeine does not produce an additional effect on blood pressure
or heart rate beyond the effect of caffeine alone [41]. All this information suggests that
p-synephrine/Citrus aurantium are safe substances for acute and chronic ingestion in doses
up to 1–3 mg/kg of body mass. Nevertheless, it is important to inform potential users of
thermogenics and weight-loss products that other harmful stimulants may be included
in commercially available dietary supplements, even when there is no information of the
inclusion of these potentially dangerous substances on the label. The authenticity/quality
assurance of dietary supplements containing p-synephrine [15], especially in those with
a multi-ingredient formula, is key to avoiding potential side effects. The use of dietary
supplements with pure p-synephrine is recommended to obtain its benefits on fat oxidation
while reducing the likelihood of harmful effects due to the inclusion of other stimulants.
7. Conclusions
In summary, acute p-synephrine ingestion increases the reliance on fat, while reducing
carbohydrate use as fuel during low- to moderate-intensity exercise. The enhancement
in fat utilization with p-synephrine is normally obtained without any changes in Fatmax,
likely due to the lack of this substance to increase exercise performance. The p-synephrine
also reduces the rate of carbohydrate oxidation during exercise of low to moderate in-
tensity while energy expenditure and heart rate are generally unchanged. The effect of
p-synephrine to shift substrate oxidation has been found during ramp exercise tests and
during steady-state exercise.
From a practical perspective, the acute use of p-synephrine might offer some benefits
for those individuals seeking higher fat utilization during exercise. The use of this phy-
tochemical, at doses of up to 3 mg/kg, offers some benefits over other substances such
as caffeine due to the lower rate of side effects associated with the former. Although the
magnitude of the effect p-synephrine on fat oxidation during exercise is small (increase
of fat oxidation ~0.1 g/min), the use of p-synephrine-containing supplements may be an
option to maximize fat oxidation. However, more research is necessary to determine if the
effect of p-synephrine on fat oxidation during exercise is maintained with chronic ingestion,
in order to ascertain the utility of this substance in conjunction with exercise programs to
produce an effective body fat/weight loss reduction. Lastly, more translational research is
also necessary to ascertain whether the lower carbohydrate use with p-synephrine produces
significant glycogen sparing that may be effective to enhance performance in endurance
sports competition.
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